Seed Grants catalyze collaborations between researchers from across the university for innovative, collaborative research projects in the neurosciences.
Funded Seed Grant projects
Use of gut-brain electrophysiology to study interoception in eating disorders
In this study, we aim to (i) perform a feasibility study to determine the acceptance and feasibility of performing such recordings in the AN and ARFID eating disorders population and (ii) test the hypothesis that the electrophysiologic monitoring of the brain and stomach is associated with a clinically validated behavioral measure of interoception involving water distention of the stomach.
Life-long, minimally invasive, and multiplex transcriptional profiling of the cerebellum
Why do all our brains mature and age in different ways, leading to different cognitive and behavioral outcomes? We envision a novel method that “copies” the information from the RNAs made by the neurons to sensor RNAs we artificially introduce into live animals.
Novel ketone-derived anticonvulsant agents for the treatment of childhood refractory epilepsy
We propose to apply mass spectrometry techniques to measure BHB-Phe and other KD metabolites in children undergoing KD for refractory epilepsy at Stanford. Further, in a mouse model of refractory genetic epilepsy, we will compare targeted BHB-Phe treatment to full KD treatment using transcriptomics, EEG assessment of seizures and cognitive testing.
Dissecting mechanisms of gut-brain communication in Parkinson’s Disease
People with Parkinson’s Disease (PD) have different types of bacteria in their guts compared to people without neurological diseases. We will study which gut bacteria for people with PD to gain a better understanding of how gut bacteria contribute to inflammation in the body and in the brain or people with this condition.
Structural and mechanistic analysis of the protein-protein interface between ABCA1 and ApoE as a potential therapeutic target for Alzheimer’s Disease
We propose a new line of research whose goal is to examine the druggability of a protein-protein interface involving ApoE, an apolipoprotein whose gene variants represent the strongest genetic risk factor for AD.